Buyer guide
Reviewed March 19, 2026 · GLP-1-related peptide sourcing risk
GLP-1 peptide purity and COA checks
Purity claims are often treated like the whole answer in GLP-1-related peptide sourcing. They are not. Buyers should interpret purity claims inside a larger qualification question: who made the material, what batch the COA refers to, how it was handled, and whether the testing story is coherent enough to support a PO.
What a buyer should check
- Is the COA tied to a real lot and supplier entity?
- Are purity and assay values presented with enough context to interpret them?
- Do the COA, quote, invoice path, and shipment story align?
- Is the document packet strong enough to support the order without deeper verification?
Typical source pages reviewed
For this type of buyer screen, APV typically compares the quote packet, COA/specification sheet, entity and invoice details, shipment/storage statements, and any public quality or manufacturing claims used in the sales story.
Common buyer mistakes
- Treating a high purity number as proof that the supplier risk is solved.
- Ignoring missing method context or weak traceability.
- Failing to compare the COA to the commercial and shipping packet.
When a paid screen is justified
- The COA is central to supplier selection.
- The first PO is meaningful.
- The document packet still leaves uncertainty about batch identity, handling, or testing credibility.